Design Therapeutics, Inc. — Director's Dealing 2021

Apr 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Design Therapeutics, Inc. (DSGN)
CIK: 0001807120
Period of Report: 2021-03-30

Reporting Person: Jeffries Sean (Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-30	Common Stock	P	3050	$20.00	Acquired	3050	Indirect

Footnotes

F1: The shares were purchased in the Issuer's initial public offering.